PERTINENT FINDINGS: uPAR antibody uptake is increased when the pancreatic cancers tested are administered a senescence-inducing TP signifying uPAR as both an oncology target and a senescence target. The gene discussed is PLAUR; the disease is pancreatic neoplasm.